News on altimmune
Witryna11 kwi 2024 · GAITHERSBURG, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the … Witryna14 kwi 2024 · Altimmune Inc. (NASDAQ:ALT) shares, rose in value on Thursday, 04/13/23, with the stock price up by 12.17% to the previous day’s close as strong …
News on altimmune
Did you know?
Witryna13 kwi 2024 · Insider Transactions at Altimmune. In related news, Director David Drutz bought 9,000 shares of the stock in a transaction that occurred on Thursday, March … Witryna11 kwi 2024 · GAITHERSBURG, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the …
Witryna22 mar 2024 · Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation ... Witryna21 mar 2024 · Altimmune ( NASDAQ: ALT) stock fell ~35% premarket on Tuesday after the company reported data from a phase 2 trial and phase 1b study of its obesity therapy pemvidutide. The study, dubbed MOMENTUM ...
Witryna11 kwi 2024 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and … Witryna21 mar 2024 · What Happened: In pre-market trading, the stock of the troubled regional bank plunged 21.58% to $18.06, according to Benzinga Pro data. The stock shed a …
Witryna8 sty 2024 · Altimmune Inc. published this content on 08 January 2024 and is solely responsible for the information contained therein. Distributed by Public, ... More news: Analyst Recommendations on ALTIMMUNE, INC. 01/20: HC Wainwright Reiterates Altimmune at Buy With $50 Price Target: MT. 01/18:
Witryna29 cze 2024 · Altimmune also provides an update on its T-COVID™ Phase 1/2 Clinical Trial; GAITHERSBURG, Md., June 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, … bis 2-methoxyethyl ether sdsWitryna21 mar 2024 · What Happened: In pre-market trading, the stock of the troubled regional bank plunged 21.58% to $18.06, according to Benzinga Pro data. The stock shed a whopping 32.80% on Friday despite private ... bis 2-methoxyethyl ether 構造Witryna4 maj 2024 · On January 19, 2024, certain of Altimmune's stockholders, owning 68% of the outstanding shares of Altimmune capital stock, agreed to vote their shares in favor of the adoption of the merger agreement. As of February 2, 2024, all Directors and Executive Officers of Altimmune owning approximately 66% agreed to vote in favor … bis 2-methyl-3-furyl disulfideWitryna11 kwi 2024 · GAITHERSBURG, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB). … bis 2-methoxyethyl amino sulfur trifluorideWitrynaThe mean of analysts' price targets for Altimmune, Inc. (ALT) points to a 352.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, … bis 2-n-butoxyethyl phthalateWitrynaView the latest Altimmune Inc. (ALT) stock price, news, historical charts, analyst ratings and financial information from WSJ. bis 2 methoxyethyl amino sulfur trifluorideWitrynaFind the latest Altimmune, Inc. (ALT) stock quote, history, news and other vital information to help you with your stock trading and investing. dark blue aesthetic outfits